[Federal Register Volume 67, Number 161 (Tuesday, August 20, 2002)]
[Notices]
[Page 53950]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-21083]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


A Public Health Action Plan To Combat Antimicrobial Resistance 
(Part II: Global Issues): Meeting for Public Comment on Development of 
Part II of the Action Plan (Global Issues)

    The Centers for Disease Control and Prevention (CDC), Food and Drug 
Administration (FDA), and National Institutes of Health (NIH) announce 
an open meeting concerning antimicrobial resistance.

    Name: A Public Health Action Plan To Combat Antimicrobial 
Resistance (Part II: Global Issues): Meeting for Public Comment on 
the Development of Part II of the Action Plan (Global Issues).
    Time and Date: 8:30 a.m.-3:30 p.m., September 26, 2002.
    Place: Manchester Grand Hyatt, Manchester Ballroom A & B, 8120 
One Market Place, San Diego, California, 92101, U.S.A. Tel: 619-232-
1234; Fax: 619-232-5678.
    Status: Open to the public, interested experts who are citizens 
of the United States or other countries are welcomed and encouraged 
to attend. Limited only by the space available.
    Purpose: To solicit comments to aid in the development of A 
Public Health Action Plan to Combat Antimicrobial Resistance (Part 
II: Global Issues). The Action Plan serves as a blueprint for 
specific actions of U.S. government agencies to address the global 
problem of antimicrobial resistance.
    Matters to be Discussed: The agenda will consist of welcome and 
introductory comments, focusing on the three areas that comprise 
Part II of the Action Plan, lasting about 90 minutes. The three 
focus areas are: Surveillance, Prevention and Control, and Research. 
Breakout groups will then meet to discuss each focus area for 
approximately 3 hours. Following lunch, the entire group will 
reconvene for a concluding plenary session lasting approximately 2 
hours.
    Comments and suggestions from the public for Federal agencies 
related to each of the focus areas will be taken under advisement by 
the Antimicrobial Resistance Interagency Task Force. The agenda does 
not include development of consensus positions, guidelines, or 
discussions or endorsement of specific commercial products.
    The Action Plan (Part I: Domestic Issues) is available at http://www.cdc.gov/drugresistance. The public meeting is sponsored by the 
CDC, FDA, and NIH in collaboration with eight other Federal agencies 
and departments involved in developing and writing A Public Health 
Action Plan to Combat Antimicrobial Resistance (Part II: Global 
Issues).
    Agenda items are subject to change as priorities dictate.
    Limited time will be available for oral questions, comments, and 
suggestions from the public. Depending on the number wishing to 
comment, a time limit may be imposed. In the interest of time, 
visual aids will not be permitted, although written material may be 
submitted for subsequent review by the Task Force. Written comments 
and suggestions from the public are encouraged and should be 
received by the contact person or email listed below prior to the 
opening of the meeting or no later than the end of October 2002.
    Persons who anticipate attending the meeting are requested to 
send written notification to the contact person below by September 
23, 2002, including name, organization (if applicable), address, 
phone, fax, and email address.
    Contact Person for More Information: Ms. Vickie Garrett, 
Antimicrobial Resistance, Office of the Director, NCID, CDC, 
Mailstop C-12, 1600 Clifton Road, NE., Atlanta, GA 30333; telephone 
404-639-2603; fax 404-639-4197; or e-mail [email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining 
to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

    Dated: August 14, 2002.
Joseph E. Salter,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 02-21083 Filed 8-19-02; 8:45 am]
BILLING CODE 4163-18-P